NK Cell Infusion for Patients With Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Natural killer (NK) cells exert antitumor effects via their cytotoxic and cytokine-secreting
capacity without present of clinical symptoms. In recent years, with the continuous
advancement of in vitro expansion methods, the application of good quality management
technology, NK cells could be clinical grade expanded without the need for pre-purification,
feeder-free, and serum-free culture. In this clinical trial the investigators want to
demonstrate the safety and efficacy chemotherapy combined with donor-derived in vitro
activated NK cells infusion for high risk AML patients.